In the latest session, Arcus Biosciences Inc (NYSE: RCUS) closed at $17.72 down -4.11% from its previous closing price of $18.48. In other words, the price has decreased by -$0.76 from its previous closing price. On the day, 891407 shares were traded. RCUS stock price reached its highest trading level at $18.26 during the session, while it also had its lowest trading level at $17.57.
Ratios:
For a deeper understanding of Arcus Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.52 and its Current Ratio is at 4.52. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on November 18, 2022, initiated with a Neutral rating and assigned the stock a target price of $33.
On October 11, 2022, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $40.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 27 ’24 when Jarrett Jennifer sold 11,551 shares for $17.55 per share. The transaction valued at 202,720 led to the insider holds 215,253 shares of the business.
Jarrett Jennifer sold 13,449 shares of RCUS for $240,941 on Mar 18 ’24. The Chief Operating Officer now owns 226,804 shares after completing the transaction at $17.92 per share. On Feb 27 ’24, another insider, Jarrett Jennifer, who serves as the Chief Operating Officer of the company, sold 34,070 shares for $20.11 each. As a result, the insider received 685,148 and left with 240,253 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 1.61B and an Enterprise Value of 862.12M. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.76 while its Price-to-Book (P/B) ratio in mrq is 2.90. Its current Enterprise Value per Revenue stands at 7.37 whereas that against EBITDA is -2.96.
Stock Price History:
Over the past 52 weeks, RCUS has reached a high of $25.47, while it has fallen to a 52-week low of $12.95. The 50-Day Moving Average of the stock is 17.18, while the 200-Day Moving Average is calculated to be 17.89.
Shares Statistics:
For the past three months, RCUS has traded an average of 877.98K shares per day and 690.14k over the past ten days. A total of 75.50M shares are outstanding, with a floating share count of 47.32M. Insiders hold about 47.92% of the company’s shares, while institutions hold 54.44% stake in the company. Shares short for RCUS as of Mar 15, 2024 were 7.98M with a Short Ratio of 9.09, compared to 7.52M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.79% and a Short% of Float of 13.18%.
Earnings Estimates
There are 8 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.94 for the current quarter, with a high estimate of -$0.42 and a low estimate of -$1.21, while EPS last year was -$1.09. The consensus estimate for the next quarter is -$0.58, with high estimates of $2.21 and low estimates of -$1.26.
Analysts are recommending an EPS of between -$1.28 and -$4.92 for the fiscal current year, implying an average EPS of -$3.52. EPS for the following year is -$4.27, with 9 analysts recommending between -$2.41 and -$5.99.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $35.56M this quarter.It ranges from a high estimate of $72.5M to a low estimate of $25M. As of the current estimate, Arcus Biosciences Inc’s year-ago sales were $25M, an estimated increase of 42.20% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $29.7M, a decrease of -2.00% less than the figure of $42.20% in the same quarter last year. There is a high estimate of $40M for the next quarter, whereas the lowest estimate is $22.5M.
A total of 9 analysts have provided revenue estimates for RCUS’s current fiscal year. The highest revenue estimate was $502.19M, while the lowest revenue estimate was $100M, resulting in an average revenue estimate of $191.65M. In the same quarter a year ago, actual revenue was $117M, up 63.80% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $166.61M in the next fiscal year. The high estimate is $524.84M and the low estimate is $90M. The average revenue growth estimate for next year is down -13.10% from the average revenue estimate for this year.
